Akston Biosciences
US-based Akston Biosciences develops and manufactures innovative biologics, vaccines, and therapies.
Founded
2011US-based Akston Biosciences develops and manufactures innovative biologics, vaccines, and therapies.
Founded in Beverly, United States, Akston Biosciences leverages its novel fusion protein platform to develop and manufacture innovative biologics. The company focuses on creating breakthrough protein therapeutics, including vaccines, ultra-long-acting insulins, and therapies for autoimmune diseases. Akston's core mission is to accelerate the development and commercialization of these biologics, particularly in the Companion Animal Health market, through its integrated capabilities and strategic partnerships.
Notable affiliated individuals and investors include experts in biologics and animal health, though specific names are not provided. Key achievements include the establishment of a GMP manufacturing facility dedicated to Animal Health, significantly reducing the time from discovery to commercial manufacturing. Akston Biosciences has made a substantial impact by advancing the field of protein therapeutics and forming strategic partnerships that enhance its innovation and market reach.
Companies similar to Akston Biosciences include Sunflower Therapeutics, Abcombi Biosciences, GRO Biosciences and Traverse Biosciences.
Akston Biosciences was founded in 2011.
Akston Biosciences' headquarters is located in Beverly, MA, US.
Akston Biosciences' most recent funding round was for $5.2M (USD) in April 2022.
As of Apr 14, 2022, Akston Biosciences has disclosed funding of $46.6M (USD). Undisclosed round amounts are excluded.
Akston Biosciences has 67 employees as of Feb 5, 2024.
Traverse Biosciences
